Articles 6 versus 12 months of adjuvant trastuzumab for HER2positive early breast cancer PERSEPHONE 4year diseasefree survival results of a randomised phase 3 noninferiority trial

[Articles] 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

21:05 EDT 6 Jun 2019 | The Lancet

We have shown that 6-month trastuzumab treatment is non-inferior to 12-month treatment in patients with HER2-positive early breast cancer, with less cardiotoxicity and fewer severe adverse events. These results support consideration of reduced duration trastuzumab for women at similar risk of recurrence as to those included in the trial.

More From BioPortfolio on "[Articles] 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial"